| Hans-Günter Meyer-Thompson | HIV
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial
Margolis, David A et al.
The Lancet , Volume 0 , Issue 0 , Published: 24 July 2017
doi.org/10.1016/S0140-6736(17)31917-7
http://thelancet.com/journals/lancet/article/PIIS0140-6736(17)31917-7/fulltext